Corbus Pharmaceuticals Holdings (LTS:0SZI) Net Income From Continuing Operations : $-50.29 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Corbus Pharmaceuticals Holdings's net income from continuing operations for the three months ended in Mar. 2025 was $-16.98 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was $-50.29 Mil.

Corbus Pharmaceuticals Holdings Net Income From Continuing Operations Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Net Income From Continuing Operations Chart

Corbus Pharmaceuticals Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

-111.27

-45.64

-42.35

-44.60

-40.21

Corbus Pharmaceuticals Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															-6.90	-10.00	-13.78	-9.53	-16.98

Corbus Pharmaceuticals Holdings Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.29 Mil.

Corbus Pharmaceuticals Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (LTS:0SZI) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

CRBP:USA 3371:Germany

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings Headlines

No Headlines